Hormone Replacement Therapy (HRT) is medically justified medical treatment that has been in use for a long time in the treatment of various health conditions, such as menopause, endocrine and gender-affirming care. However, when appropriately prescribed and supervised by trained health care personnel, HRT is held to be safe and is much more effective in enhancing quality of life. But in India, having access to supervised treatment is challenging because of structural barriers of stigma, lack of specialised providers, financial barriers, and bureaucratic impediments affecting most people going through transgender issues. This leads to the situation where some of them embark on hormone therapy without medical attention, posing a risk to their health as well as a matter of concern to the entire population of the country.

Gender-Affirming Hormone Therapy: Purpose and Benefits

GAHT is used to align the physical appearance to the gender identity of an individual and is heavily linked with negative gender dysphoria and the enhancement of the overall psychological well-being.

Transfeminine therapy typically incorporates estrogen and testosterone-blocking medications, which affect slow architectural changes, including the development of breasts, reddening of the skin and the redistribution of fat.

Transmasculine therapy entails the use of testosterone, which makes the voice deep, muscles grow in size, body hair develops, and menstruation stops.

Such changes in physiology take place over months and years, so detailed control by using blood tests is needed to provide an appropriate drug dosage and reduce the risks of cardiovascular diseases or liver anomalies.

Structural Barriers Leading to Unsupervised Hormone Use

Limited Availability of Trained Providers

Gender-affirming healthcare services remain concentrated in large metropolitan centres. Many smaller cities and rural regions lack endocrinologists or clinics trained in transgender healthcare, forcing individuals to travel long distances for care.

Financial Constraints

Consultations, diagnostic tests, and long-term hormone therapy can be expensive. Since many transgender individuals face employment discrimination and economic marginalisation, formal healthcare services may be unaffordable, encouraging reliance on over-the-counter medication access.

Stigma and Discrimination in Healthcare Settings

Negative experiences such as misgendering, refusal of treatment, or insensitive provider behaviour discourage individuals from seeking hospital-based care. Fear of discrimination often leads people to seek advice from peers rather than professionals.

Administrative and Documentation Barriers

Complex documentation processes, long waiting periods for appointments, and limited awareness of government health schemes further delay treatment initiation, pushing individuals toward self-medication.

Community-Based Informal Hormone Access

Composite Case Example (based on community health reports):

The patient is a 24-year-old transgender female residing in a Tier-2 Indian city and wants to initiate feminising hormone therapy. The closest state-run hospital that provides the services of transgender health is a few hundred kilometres distant, and even the private clinics will cost her over fifty per cent of her monthly salary to consult. She is advised on hormone pills to use through the local community networks, and she would buy them directly through pharmacies that do not need rigid prescription to make necessary purchases.

First, she feels a lot relieved psychologically and less dysphoric. But after a few months, she experiences symptoms like headaches and irregular blood pressure. It is hard without regular laboratory tests to make alterations regarding dosage. At a later stage, she is referred to a qualified endocrinologist by an NGO-organised health camp that also caters to her current screening. This case demonstrates the way people tend to rely on informal systems, not because they are preferable, but because they have few essential options.

Public Health and Policy Implications

Self-prescription of hormones may lead to further complications in terms of inappropriate use, combination of medications, and non-diagnosed primary issues. In a public-health sense, this problem does not lie in the demand for hormone therapy either, since gender-affirming medical care is medically recognised, but in the shortages of available, affordable, and free-of-stigma medical services.

Transgender-inclusive healthcare education, incorporating gender-affirming care into community hospitals, better insurance access, and enhanced partnerships between the community and clinics can lead to a reduction in the use of informal networks for accessing hormones.

“Hormones without doctors” reflects systemic healthcare access challenges rather than individual irresponsibility. Gender-affirming hormone therapy is a medically validated treatment that improves mental health and overall well-being when properly supervised. Ensuring equitable access to trained providers, affordable treatment, and respectful healthcare environments is essential for improving both individual outcomes and broader public-health systems. As India gradually expands transgender healthcare services, strengthening institutional support and reducing stigma will be key to transforming gender-affirming care into routine, accessible healthcare for all.

References:

• American College of Obstetricians and Gynaecologists. (2021). Health care for transgender and gender diverse individuals. https://www.acog.org
• Coleman, E., Radix, A. E., Bouman, W. P., Brown, G. R., de Vries, A. L. C., Deutsch, M. B., Arcelus, J., et al. (2022). Standards of care for the health of transgender and gender diverse people, Version 8. International Journal of Transgender Health, 23(Suppl 1), S1–S259. https://www.wpath.org
• Hembree, W. C., Cohen-Kettenis, P. T., Gooren, L., Hannema, S. E., Meyer, W. J., Murad, M. H., Rosenthal, S. M., Safer, J. D., Tangpricha, V., & T’Sjoen, G. G. (2017). Endocrine treatment of gender-dysphoric/gender-incongruent persons: An Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism, 102(11), 3869–3903. https://academic.oup.com
• Johns Hopkins Medicine. (n.d.). Gender-affirming hormone therapy (GAHT). https://www.hopkinsmedicine.org
• World Professional Association for Transgender Health. (2022). Standards of care for the health of transgender and gender diverse people (SOC-8). https://wpath.org

.    .    .